Skip to main content

ORBIMED ADVISORS LLC

Position in PTGX — Protagonist Therapeutics, Inc

CIK 1055951 New York, NY

Position in PTGX

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$5,160,618
+$723,278 QoQ
Shares Held
42,100
0.0% QoQ
Ownership
0.065%
of shares outstanding
% of Portfolio
0.10%
of 13F equity value
Holder Rank
#101
of 341 holders
Holding Since
Mar 2020
5 quarters on record
Voting authority Sole 0% Shared 0% None 100%

Common Shares in PTGX Over Time

Shares Held

Position Value (USD)

Derivatives in PTGX

reported options exposure · as of Jun 30, 2026
CallValue
$18,387,000
CallShares
150,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

ORBIMED ADVISORS LLC holds $3,639,640,835 across 90 Biotechnology names. PTGX ranks #72 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in PTGX

Export CSV
6 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $5,160,618 42,100
2026-06-30 $18,387,000 150,000
2026-03-31 $4,437,340 42,100
2025-12-31 $1,895,278 21,700
2023-03-31 $6,923,000 301,000
2020-03-31 $472,377 66,909